UBS Group’s Molecular Partners MOLN Stock Holding History

UBS Group’s Portfolio MOLN Stock Details MOLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08K	Buy	+279	New	+$1.13K	﹤0.01%	9636
2026 Q1	–	Sell	-349	Closed	-$1.52K	–	10925
2025 Q4	$1.52K	Sell	349 -4,990	-93%	-$20.4K	﹤0.01%	9552
2025 Q3	$19.8K	Sell	5,339 -4,860	-48%	-$18K	﹤0.01%	8161
2025 Q2	$39K	Buy	10,199 +3,848	+61%	+$14.8K	﹤0.01%	7978
2025 Q1	$24.6K	Sell	6,351 -521	-8%	-$2.52K	﹤0.01%	8090
2024 Q4	$32.6K	Buy	6,872 +1,626	+31%	+$8.95K	﹤0.01%	7548
2024 Q3	$26.7K	Buy	5,246 +1,785	+52%	+$10.9K	﹤0.01%	7183
2024 Q2	$25K	Buy	3,461 +3,135	+962%	+$14.7K	﹤0.01%	7156
2024 Q1	$1.26K	Buy	+326	New	+$1.44K	﹤0.01%	8172
2023 Q1	–	Sell	-2,958	Closed	-$19.4K	–	10063
2022 Q4	$19.4K	Buy	+2,958	New	+$19.2K	﹤0.01%	7677
2022 Q2	–	Sell	-611	Closed	-$12K	–	10687
2022 Q1	$12K	Sell	611 -2,796	-82%	-$67.9K	﹤0.01%	8193
2021 Q4	$65K	Buy	+3,407	New	+$57.3K	﹤0.01%	6686
2021 Q3	–	Sell	-23	Closed	–	–	9866
2021 Q2	$0	Buy	+23	New	+$456	﹤0.01%	9639

Other funds holding MOLN

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's MOLN Position: Q2 2026 in Review

UBS Group opened a new position in Molecular Partners (MOLN) in Q2 2026: 279 shares worth $1.08K. The stake represents ﹤0.01% of the portfolio and ranks #9636 among its holdings. This is a return to the name: UBS Group previously reported a position in MOLN as recently as Q4 2025.

UBS Group first reported a position in MOLN in Q2 2021 and has held it in 13 quarters since. The position peaked at $65K in Q4 2021. 5 funds tracked by Wall St. Rank hold MOLN as of Q2 2026.

UBS Group held 279 shares of Molecular Partners worth $1.08K as of Q2 2026.
Molecular Partners was a new UBS Group position in Q2 2026.
Molecular Partners made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9636 holding.
UBS Group first reported a position in Molecular Partners in Q2 2021 and has held it in 13 quarters since.
UBS Group's Molecular Partners position peaked at $65K in Q4 2021.
5 funds tracked by Wall St. Rank held Molecular Partners as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.